Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

The five stages of chronic kidney disease (CKD) indicate how well the kidneys are working, ranging from stage 1 (mild kidney ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

Ozempic is approved to reduce the risk of heart attack or stroke in people with type 2 diabetes and heart disease. It’s also approved to reduce the risk of kidney disease progression or heart ...